Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia
Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2010-09, Vol.73 (3), p.369-374 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 374 |
|---|---|
| container_issue | 3 |
| container_start_page | 369 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 73 |
| creator | TAN, Tricia CABRITA, Ines Z MARTIN, Niamh M HENSMAN, Davina GROGONO, Joanna DHILLO, Waljit S BAYNES, Kevin C ELIAHOO, Joseph MEERAN, Karim ROBINSON, Stephen NIHOYANNOPOULOS, Petros |
| description | Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy.
Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer.
Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology.
Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet.
Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia. |
| doi_str_mv | 10.1111/j.1365-2265.2010.03827.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00552608v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>749000669</sourcerecordid><originalsourceid>FETCH-LOGICAL-h274t-10d90370e43512ac2c39f4f9c083e995e8fdc1cb32d1569ec444e04c7bc9d52b3</originalsourceid><addsrcrecordid>eNpF0E1P3DAQBmCrApUt9C9UviDUQ7bjryQ-rhCFSitxKedo4kxY08RZ7Oyq--8xsKW-WBo_fjV6GeMCliKfH09LoUpTSFmapYQ8BVXLavn3E1t8PJywBSiAAspSn7EvKT0BgKmh-szOJBgDRtUL9meVEqU0Upj51HOHsfPo-B6HPfHukPpdcLOfAveBb3H22SUeyZHf-_CYfUvxcRp8ID5HwvktqJ8i3xy2FLdxGjD_D0ijxwt22uOQ6OvxPmcPP29-X98V6_vbX9erdbGRlZ4LAZ0FVQFpZYREJ52yve6tg1qRtYbqvnPCtUp2wpSWnNaaQLuqdbYzslXn7Pt77gaHZhv9iPHQTOibu9W6eZ3lHowsod6LbK_ebV71eUdpbkafHA0DBpp2qam0zbWVpc3y21Hu2pG6j-B_XWZweQSYHA59xOB8-u8UWCGlUS9AuYYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>749000669</pqid></control><display><type>article</type><title>Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>TAN, Tricia ; CABRITA, Ines Z ; MARTIN, Niamh M ; HENSMAN, Davina ; GROGONO, Joanna ; DHILLO, Waljit S ; BAYNES, Kevin C ; ELIAHOO, Joseph ; MEERAN, Karim ; ROBINSON, Stephen ; NIHOYANNOPOULOS, Petros</creator><creatorcontrib>TAN, Tricia ; CABRITA, Ines Z ; MARTIN, Niamh M ; HENSMAN, Davina ; GROGONO, Joanna ; DHILLO, Waljit S ; BAYNES, Kevin C ; ELIAHOO, Joseph ; MEERAN, Karim ; ROBINSON, Stephen ; NIHOYANNOPOULOS, Petros</creatorcontrib><description>Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy.
Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer.
Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology.
Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet.
Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/j.1365-2265.2010.03827.x</identifier><identifier>PMID: 20550538</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford: Blackwell</publisher><subject>Adult ; Antiparkinson Agents - adverse effects ; Antiparkinson Agents - therapeutic use ; Biological and medical sciences ; Blood Pressure ; Cardiology. Vascular system ; Cross-Sectional Studies ; Dose-Response Relationship, Drug ; Echocardiography ; Endocrinopathies ; Ergolines - adverse effects ; Ergolines - therapeutic use ; Female ; Fundamental and applied biological sciences. Psychology ; Heart ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Heart Valve Diseases - chemically induced ; Heart Valve Diseases - diagnosis ; Heart Valve Diseases - physiopathology ; Heart Valves - diagnostic imaging ; Heart Valves - drug effects ; Heart Valves - physiopathology ; Humans ; Hyperprolactinemia - drug therapy ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Male ; Medical sciences ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Prospective Studies ; Risk Assessment - methods ; Ventricular Function, Left ; Ventricular Function, Right ; Vertebrates: endocrinology</subject><ispartof>Clinical endocrinology (Oxford), 2010-09, Vol.73 (3), p.369-374</ispartof><rights>2015 INIST-CNRS</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23091225$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20550538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00552608$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>TAN, Tricia</creatorcontrib><creatorcontrib>CABRITA, Ines Z</creatorcontrib><creatorcontrib>MARTIN, Niamh M</creatorcontrib><creatorcontrib>HENSMAN, Davina</creatorcontrib><creatorcontrib>GROGONO, Joanna</creatorcontrib><creatorcontrib>DHILLO, Waljit S</creatorcontrib><creatorcontrib>BAYNES, Kevin C</creatorcontrib><creatorcontrib>ELIAHOO, Joseph</creatorcontrib><creatorcontrib>MEERAN, Karim</creatorcontrib><creatorcontrib>ROBINSON, Stephen</creatorcontrib><creatorcontrib>NIHOYANNOPOULOS, Petros</creatorcontrib><title>Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy.
Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer.
Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology.
Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet.
Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia.</description><subject>Adult</subject><subject>Antiparkinson Agents - adverse effects</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure</subject><subject>Cardiology. Vascular system</subject><subject>Cross-Sectional Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>Echocardiography</subject><subject>Endocrinopathies</subject><subject>Ergolines - adverse effects</subject><subject>Ergolines - therapeutic use</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Heart Valve Diseases - chemically induced</subject><subject>Heart Valve Diseases - diagnosis</subject><subject>Heart Valve Diseases - physiopathology</subject><subject>Heart Valves - diagnostic imaging</subject><subject>Heart Valves - drug effects</subject><subject>Heart Valves - physiopathology</subject><subject>Humans</subject><subject>Hyperprolactinemia - drug therapy</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Prospective Studies</subject><subject>Risk Assessment - methods</subject><subject>Ventricular Function, Left</subject><subject>Ventricular Function, Right</subject><subject>Vertebrates: endocrinology</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1P3DAQBmCrApUt9C9UviDUQ7bjryQ-rhCFSitxKedo4kxY08RZ7Oyq--8xsKW-WBo_fjV6GeMCliKfH09LoUpTSFmapYQ8BVXLavn3E1t8PJywBSiAAspSn7EvKT0BgKmh-szOJBgDRtUL9meVEqU0Upj51HOHsfPo-B6HPfHukPpdcLOfAveBb3H22SUeyZHf-_CYfUvxcRp8ID5HwvktqJ8i3xy2FLdxGjD_D0ijxwt22uOQ6OvxPmcPP29-X98V6_vbX9erdbGRlZ4LAZ0FVQFpZYREJ52yve6tg1qRtYbqvnPCtUp2wpSWnNaaQLuqdbYzslXn7Pt77gaHZhv9iPHQTOibu9W6eZ3lHowsod6LbK_ebV71eUdpbkafHA0DBpp2qam0zbWVpc3y21Hu2pG6j-B_XWZweQSYHA59xOB8-u8UWCGlUS9AuYYg</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>TAN, Tricia</creator><creator>CABRITA, Ines Z</creator><creator>MARTIN, Niamh M</creator><creator>HENSMAN, Davina</creator><creator>GROGONO, Joanna</creator><creator>DHILLO, Waljit S</creator><creator>BAYNES, Kevin C</creator><creator>ELIAHOO, Joseph</creator><creator>MEERAN, Karim</creator><creator>ROBINSON, Stephen</creator><creator>NIHOYANNOPOULOS, Petros</creator><general>Blackwell</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20100901</creationdate><title>Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia</title><author>TAN, Tricia ; CABRITA, Ines Z ; MARTIN, Niamh M ; HENSMAN, Davina ; GROGONO, Joanna ; DHILLO, Waljit S ; BAYNES, Kevin C ; ELIAHOO, Joseph ; MEERAN, Karim ; ROBINSON, Stephen ; NIHOYANNOPOULOS, Petros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h274t-10d90370e43512ac2c39f4f9c083e995e8fdc1cb32d1569ec444e04c7bc9d52b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Antiparkinson Agents - adverse effects</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure</topic><topic>Cardiology. Vascular system</topic><topic>Cross-Sectional Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>Echocardiography</topic><topic>Endocrinopathies</topic><topic>Ergolines - adverse effects</topic><topic>Ergolines - therapeutic use</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Heart Valve Diseases - chemically induced</topic><topic>Heart Valve Diseases - diagnosis</topic><topic>Heart Valve Diseases - physiopathology</topic><topic>Heart Valves - diagnostic imaging</topic><topic>Heart Valves - drug effects</topic><topic>Heart Valves - physiopathology</topic><topic>Humans</topic><topic>Hyperprolactinemia - drug therapy</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Prospective Studies</topic><topic>Risk Assessment - methods</topic><topic>Ventricular Function, Left</topic><topic>Ventricular Function, Right</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TAN, Tricia</creatorcontrib><creatorcontrib>CABRITA, Ines Z</creatorcontrib><creatorcontrib>MARTIN, Niamh M</creatorcontrib><creatorcontrib>HENSMAN, Davina</creatorcontrib><creatorcontrib>GROGONO, Joanna</creatorcontrib><creatorcontrib>DHILLO, Waljit S</creatorcontrib><creatorcontrib>BAYNES, Kevin C</creatorcontrib><creatorcontrib>ELIAHOO, Joseph</creatorcontrib><creatorcontrib>MEERAN, Karim</creatorcontrib><creatorcontrib>ROBINSON, Stephen</creatorcontrib><creatorcontrib>NIHOYANNOPOULOS, Petros</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TAN, Tricia</au><au>CABRITA, Ines Z</au><au>MARTIN, Niamh M</au><au>HENSMAN, Davina</au><au>GROGONO, Joanna</au><au>DHILLO, Waljit S</au><au>BAYNES, Kevin C</au><au>ELIAHOO, Joseph</au><au>MEERAN, Karim</au><au>ROBINSON, Stephen</au><au>NIHOYANNOPOULOS, Petros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>73</volume><issue>3</issue><spage>369</spage><epage>374</epage><pages>369-374</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy.
Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer.
Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology.
Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet.
Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia.</abstract><cop>Oxford</cop><pub>Blackwell</pub><pmid>20550538</pmid><doi>10.1111/j.1365-2265.2010.03827.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2010-09, Vol.73 (3), p.369-374 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00552608v1 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Antiparkinson Agents - adverse effects Antiparkinson Agents - therapeutic use Biological and medical sciences Blood Pressure Cardiology. Vascular system Cross-Sectional Studies Dose-Response Relationship, Drug Echocardiography Endocrinopathies Ergolines - adverse effects Ergolines - therapeutic use Female Fundamental and applied biological sciences. Psychology Heart Heart failure, cardiogenic pulmonary edema, cardiac enlargement Heart Valve Diseases - chemically induced Heart Valve Diseases - diagnosis Heart Valve Diseases - physiopathology Heart Valves - diagnostic imaging Heart Valves - drug effects Heart Valves - physiopathology Humans Hyperprolactinemia - drug therapy Hypothalamus. Hypophysis. Epiphysis (diseases) Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Prospective Studies Risk Assessment - methods Ventricular Function, Left Ventricular Function, Right Vertebrates: endocrinology |
| title | Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T00%3A32%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20cardiac%20valve%20dysfunction%20in%20patients%20receiving%20cabergoline%20treatment%20for%20hyperprolactinaemia&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=TAN,%20Tricia&rft.date=2010-09-01&rft.volume=73&rft.issue=3&rft.spage=369&rft.epage=374&rft.pages=369-374&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1111/j.1365-2265.2010.03827.x&rft_dat=%3Cproquest_hal_p%3E749000669%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=749000669&rft_id=info:pmid/20550538&rfr_iscdi=true |